ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.830
-0.080 (-4.19%)
Jun 9, 2025, 4:00 PM - Market closed
ProQR Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for ProQR Therapeutics stock ranges from a low of $4.00 to a high of $14. The average analyst price target of $9.00 forecasts a 391.80% increase in the stock price over the next year.
Price Target: $9.00 (+391.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ProQR Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $9 | Buy | Maintains | $15 → $9 | +391.80% | May 13, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $5 | Buy | Initiates | $5 | +173.22% | Apr 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +118.58% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +555.74% | Mar 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +501.09% | Feb 12, 2025 |
Financial Forecast
Revenue This Year
20.11M
from 19.55M
Increased by 2.87%
Revenue Next Year
14.88M
from 20.11M
Decreased by -25.97%
EPS This Year
-0.39
from -0.32
EPS Next Year
-0.47
from -0.39
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.7M | 21.0M | 20.1M | ||
| Avg | 20.1M | 14.9M | 8.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 128.7% | 4.5% | 35.2% | ||
| Avg | 2.9% | -26.0% | -40.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.25 | -0.33 | -0.36 |
| Avg | -0.39 | -0.47 | -0.51 |
| Low | -0.50 | -0.68 | -0.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.